Furthermore, despite that HAART has significantly reduced morbidity and mortality in HIV/TB patients[14], studies showed defects of immune response in HIV/TB patients on HAART including suboptimal restoration of CD4+ T cells in number, phenotype and function[15,16], and incomplete TB specific immune restoration[17]. This evidence concerns the gene CD4 and tuberculosis.